Vesilute
Aliases: Bladder peptide bioregulator
Last verified: 2026-09-24
The short version
Vesilute closes the 'bioregulator' category in this catalog and illustrates its core problem: a name without a standardized substance, a promise ('bladder') without a single human measurement, and a category (urinary aging) where real, proven approaches exist — pelvic floor training, antimuscarinic-type drugs, a urological exam. The bladder is not an organ to be 'regulated' by unknown peptides; urinary symptoms are symptoms that deserve diagnostics, not speculation.
Identity & type
- Molecular type
- bioregulator
- Origin
- Insufficiently defined — as with HEP-1, it is sold under a name covering several different preparations.
Mechanism of action
A name for peptides isolated from bladder tissue within the Khavinson bioregulator program; an effect on detrusor muscle and urothelium via 'peptide factor' signaling is claimed — a concrete molecule is not standardized in publications.
not confirmed in humans
Dosing & routes
Official / clinical context
No official context exists.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Rare; among users with mixed bioregulator courses, without measured outcomes.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
No approved protocol exists. Vesilute is a research peptide bioregulator with no registered drug product in any major market.
Duration: —
A name for bladder-derived peptides in the Khavinson program; a concrete molecule is not standardized in publications and no trial data exist.
Community (anecdotal)
5–10 mg SC daily for 10–15 days, or 1–2 mg orally per the program pattern.
- Cycle:
- Repeated courses, 1–2× per year as extrapolated from the series.
- Break:
- Months between courses.
Follows the program-pattern variant of the shared course structure; only the bladder/detrusor targeting claim distinguishes it from the rest of the series.
Human evidence
None.
Preclinical evidence
Unclear and single-source, within the 'bioregulator' literature pattern.
Known risks
- Delaying urological diagnostics for symptomstheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Everything — identity, effect, safety
Frequently asked questions
References
- Khavinson-adjacent bladder peptide literature (single-source, small animal studies)